BullFrog AI to Participate at the H.C. Wainwright 26th Annual Global Investment ConferenceGAITHERSBURG, Md., Aug. 26, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a leader in AI-driven drug discovery, announced today that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference being held in New York City.
BullFrog AI Enters into Licensing Agreement with Johns Hopkins University for Use of Novel Formulation of Mebendazole for Treatment of CancerGAITHERSBURG, MD / ACCESSWIRE / March 23, 2022 / BullFrog AI Holdings, Inc., a biopharmaceutical company focused on applying its proprietary Artificial Intelligence/Machine Learning platform to improve drug development and shorten clinical trial timelines, today announced that it has entered into an exclusive license agreement with Johns Hopkins University for use of its novel formulation of mebendazole in treating cancer. Under the terms of the
